Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $10.5714.

Several analysts recently commented on PSNL shares. HC Wainwright boosted their price target on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of Personalis in a research report on Wednesday, November 5th. Needham & Company LLC lifted their price target on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Morgan Stanley upped their price objective on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st.

Insider Buying and Selling

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. This represents a 38.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Personalis

Several institutional investors have recently modified their holdings of PSNL. American Century Companies Inc. raised its stake in shares of Personalis by 33.9% in the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after purchasing an additional 17,056 shares during the period. Trexquant Investment LP boosted its position in shares of Personalis by 455.0% during the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock worth $432,000 after buying an additional 100,804 shares during the period. Royal Bank of Canada grew its holdings in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its position in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after buying an additional 33,044 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after buying an additional 101,706 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Stock Down 1.1%

NASDAQ:PSNL opened at $8.33 on Friday. Personalis has a 12-month low of $2.83 and a 12-month high of $11.40. The firm has a market capitalization of $739.70 million, a PE ratio of -9.47 and a beta of 1.99. The firm has a 50-day moving average price of $9.00 and a 200 day moving average price of $7.10.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The company had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.31 million. On average, research analysts expect that Personalis will post -1.4 EPS for the current year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.